Theregen, inc.
Theregen, Inc. is a regenerative medicine company based in San Francisco, California, USA, that develops cell-based therapies for patients with cardiovascular and vascular disease. The company is conducting a Phase I human clinical safety trial at two US sites for its lead product, Anginera, a cell-based epicardial patch therapy. Anginera is designed to promote blood vessel growth in damaged cardiac tissue, stimulate wound healing and, potentially, to restore cardiac function in patients with heart failure.